Virus-mediated gene transfer to induce therapeutic angiogenesis: Where do we stand?

International Journal of Nanomedicine

Volumn 2, Issue 4, 2007, Pages 527-540

  Giacca, Mauro ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Adenovirus; Cardiomyocytes; Ischemia; Therapeutic angiogenesis

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; CATION; COMPLEMENTARY DNA; CONTRAST MEDIUM; CYTOKINE; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; HYPOXIA INDUCIBLE FACTOR 1; LIPID; LIPOSOME; NAKED DNA; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; PLACEBO; PLASMID DNA; POLOXAMER; PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VIRUS VECTOR;

ANGIOGENESIS; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; EXPERIMENTATION; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HEART MUSCLE CELL; HUMAN; ISCHEMIA; LEG EDEMA; NONHUMAN; REVIEW; SKELETAL MUSCLE; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANGIOGENESIS INDUCING AGENTS; ANIMALS; DNA, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; TRANSFECTION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE;

EID: 70349281951     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Amabile PG, Waugh JM, Lewis TN, et al. 2001. High-efficiency endovascular gene delivery via therapeutic ultrasound. JAm Coll Cardiol, 37:1975-80.
2. Arsic N, Zentilin L, Zacchigna S, et al. 2003. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther, 7:450-9.
3. Asahara T, Chen D, Takahashi T, et al. 1998. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF- induced postnatal neovascularization. Circ Res, 83:233-40.
4. Athanasopoulos T, Fabb S, Dickson G. 2000. Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review). Int J Mol Med, 6:363-75.
5. Ay T, Havaux X, Van Camp G, et al. 200 1. Destruction of contrast micro-bubbles by ultrasound: effects on myocardial function, coronary perfusion pressure, and microvascular integrity. Circulation, 104:461-6.
6. Baker AH. 2004. Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol, 84:279-99.
7. Barr E, Carroll J, Kalynych AM, et al. 1994. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther, 1:51-8.
8. Battler A, Scheinowitz M, Bor A, et al. 1993. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. JAm Coll Cardiol, 22:2001-6.
9. Baumgartner I, Pieczek A, Manor O, et al. 1998. Constitutive expression of phVEGF 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation, 97:1114-23.
10. Baumgartner I, Rauh G, Pieczek A, et al. 2000. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med, 132:880-4.
11. Bergelson JM, Cunningham JA, Droguett G, et al. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science, 275:1320-3.
12. Bussolino F, Serini G, Mitola S, et al. 2001. Dynamic modules and heterogeneity of function: a lesson from tyrosine kinase receptors in endothelial cells. EMBO Rep, 2:763-7.
13. Carmeliet P, Collen D. 1999. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol, 237:133-58.
14. Chen S, Shohet RV, Bekeredjian R, et al. 2003. Optimization of ultrasound parameters for cardiac gene delivery of adenoviral or plasmid deoxyribonucleic; acid by ultrasound-targeted microbubble destruction. J Am Coll Cardiol, 42:301-9.
15. Comerota AJ, Throm RC, Miller KA, et al. 2002. Naked plastilid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischen-da: preliminary results of a phase I trial. J Vasc Surg, 35:930-6.
16. Danialou G, Comtois AS, Dudley RW, et al. 2002. Ultrasound increases plasmid-mediated gene transfer to dystrophic muscles without collateral damage. Mol Ther, 6:687-93.
17. Davis S, Yancopoulos GD. 1999. The angiopoietins: Yin and Yang in angiogenesis. Curr Top Microbiol Immunol, 237:173-85.
18. Di Pasquale G, Davidson BL, Stein CS, et al. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med, 9:1306-12.
19. Ding W, Zhang L, Yan Z, et al. 2005. Intracellular trafficking of adeno-associated viral vectors. Gene Ther, 12:873-80.
20. Dumont DJ, Gradwohl G, Fong GH, et al. 1994. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev, 8:1897-909.
21. Dutheil N, Shi F, Dupressoir T, et al. 2000. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci USA, 97:4862-6.
22. Faries PL, Pomposelli FB Jr, Quist WC, et al. 2000. Assessing the role of gene therapy in the treatment of vascular disease. Ann Vasc Surg, 14:181-8.
23. Favre D, Provost N, Blouin V, et al. 2001. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther, 4:559-66.
24. Ferrara N. 1999. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol, 237:1-30.
25. Ferrari FK, Samulski T, Shenk T, et al. 1996. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol, 70:3227-34.
26. Fisher KJ, Jooss K, Alston J, et al. 1997. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med, 3:3 06-12.
27. Flotte TR, Berns KI. 2005. Adeno-associated virus: a ubiquitous commensal of mammals. Hum Gene Ther, 16:401-7.
28. Fortuin FD, Vale P, Losordo DW, et al. 2003. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in nooption patients. Am J Cardiol, 92:436-9.
29. Gale NW, Baluk P, Pan L, et al. 2001. Ephrin-132 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol, 230:151-60.
30. Gale NW, Yancopoulos GD. 1999. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev, 13:1055-66.
31. Gamble JR, Drew J, Trezise L, et al. 2000. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res, 87:603-7.
32. Gao G, Vandenberghe LH, Wilson JM. 2005. New recombinant serotypes of AAV vectors. Curr Gene Ther, 5:285-97.
33. Gilgenkrantz H, Duboc D, Juillard V, et al. 1995. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum Gene Ther, 6:1265-74.
34. Giordano FJ, Ping P, McKiman MD, et al. 1996. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med, 2:534-9.
35. Girod A, Ried M, Wobus C, et al. 1999. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med, 5:1052-6.
36. Grimm D, Kern A, Rittner K, et al. 1998. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther, 9:2745-60.
37. Grines CL, Watkins MW, Helmer G, et al. 2002. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation, 105:1291-7.
38. Grines CL, Watkins MW, Mahmarian JJ, et al. 2003. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. JAm Coll Cardiol, 42:1339-47.
39. Guzman RJ, Lemarchand P, Crystal RG, et al. 1993. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res, 73:1202-7.
40. Gyongyosi M, Khorsand A, Zarnim S, et al. 2005. NOGA-guided analysis of regional myocardial perfasion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation, 112:1157-65.
41. Hajitou A, Pasqualini R, Arap W. 2006, Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med, 16:80-8.
42. Hedman M, Hartikainen J, Syvanne M, et al. 2003. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischernia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation, 107:2677-83.
43. Henry TD, Annex BH, McKendall GR, et al. 2003. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation, 107:1359-65.
44. Huber PE, Mann MJ, Melo LG, et al. 2003. Focused ultrasound (HIFU) induces localized enhancement of reporter gene expression in rabbit carotid artery. Gene Ther, 10: 1600-7.
45. Inagaki K, Fuess S, Storm TA, et al. 2006. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther, 14:45-53.
46. Isner JM, Pieczek A, Schainfeld R, et al. 1996. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet, 348:370-4.
47. Jho D, Mehta D, Ahmmed G, et al. 2005. Angiopoictin-1 opposes VEGF-induced increase in endothelial permeability by inhibiting TRPC1-dependent Ca2 influx. Circ Res, 96:1282-90.
48. Kaludov N, Brown KE, Walters RW, et al. 2001. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol, 75:6884-93.
49. Kastrup J, Jorgensen E, Ruck A, et al. 2005. Direct intramyocardial plasmid vascular endothelial growth factor-A165 genetherapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol, 45:982-8.
50. Khan TA, Sellke FW, Laharn RJ. 2002. Therapeutic angiogenesis for coronary artery disease. 4:65-74.
51. Kotin RM, Linden RM, Berns KI. 1992, Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. Embo J, 11:5 071-8.
52. Laitinen M, Makinen K, Manninen H, et al. 1998. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther, 9:1481-6.
53. Lawrie A, Brisken AF, Francis SE, et al. 1999. Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. Circulation, 99:2617-20.
54. Lederman RJ, Mendelsohn FO, Anderson RD, et al. 2002. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet, 359:2053-8.
55. Lehrman S. 1999. Virus treatment questioned after gene therapy death. Nature, 401:517-18.
56. Linden RM, Ward P, Giraud C, et al. 1996. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA, 93:11288-94.
57. Liu Y, Cox SR, Morita T, et al. 1995. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res, 77:63 8-43.
58. Losordo DW, Vale PR, Hendel RC, et al. 2002. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation, 105:2012-18.
59. Losordo D W, Vale PR, Symes JF, et al. 1998. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation, 98:2800-4.
60. Makinen K, Manninen H, Hedman M, et al. 2002. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther, 6:127-33.
61. Marcello A, Massimi P, Banks L, et al. 2000. Adeno-associated virus type 2 Rep protein inhibits human papillomavirus type 16 E2 recruitment of the transcriptional coactivator p300. J Virol, 74:9090-8.
62. Metheny-Barlow LJ, Tian S, Hayes Al, et al. 2004. Direct chemotactic action of angiopoietin-1 on mesenchymal cells in the presence of VEGF. Microvasc Res, 68:221-30.
63. Miller DG, Trobridge GD, Petek LM, et al. 2005. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol, 79:11434-42.
64. Mitani K, Graham FL, Caskey CT, et al. 1995. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl A cad Sci USA, 92:3 854-8.
65. Miura S, Tachibana K, Okamoto T, et al. 2002. In vitro transfer of antisense oligodeoxynucleotides into coronary endothelial cells by ultrasound. Biochem Biophys Res Commun, 298:587-90.
66. Morishita R, Aoki M, Hashiya N, et al. 2004. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension, 44:203-9.
67. Neufeld G, Cohen T, Gengrinovitch S, et al. 1999. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J, 13:9-22.
68. Pajusola K, Kunnapuu J, Vuorikoski S, et al. 2005. Stabilized HIF-1 alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. Faseb J, 19:1365-7.
69. Parks RJ, Chen L, Anton M, et al. 1996. A helper-dependent adeno-virus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA, 93:13565-70.
70. Patel TH, Kimura H, Weiss CR, et al. 2005. Constitutively active HIF-1 alpha improves perfirsion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res, 68:144-54.
71. Pfeffer JM, Pfeffer MA, Fletcher PJ, et al. 1991. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol, 260: H1406-14.
72. Poellinger L, Johnson RS. 2004. HIF-I and hypoxic response: the plot thickens. Curr Opin Genet Dev, 14:81-5.
73. Qian HS, Channon K, Neplioueva V, et al. 2001. Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. Circ Res, 88:911-17.
74. Rajagopalan S, Deitcher S, Olin J, et al. 2003. Harnessing the response to hypoxia: Use of a constitutively active hypoxia-inducible factor 1-alpha transgene in no-option critical limb ischemia patients. Circulation, 108 (Suppl IV):IV, 442 (abstract).
75. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. 2003. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adeno-viral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation, 108:1933-8.
76. Rajagopalan S, Olin JW, Young S, et al. 2004. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-599 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther, 15:619-24.
77. Reilly JP, Grise MA, Fortuin FD, et al. 2005. Long-term (2-year) clinical events following transthoracic intrarnyocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol, 18:27-31.
78. Risau W. 1997. Mechanisms of angiogenesis. Nature, 386:671-4.
79. Rosengart TK, Lee LY, Patel SR, et al. 1999. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation, 100:468-74.
80. Sato K, Laham RJ, Pearlman JD, et al. 2000. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg, 70:2113-18.
81. Schnepp BC, Jensen RL, Chen CL, et al. 2005. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol, 79:14793-903.
82. Shimpo M, Ikeda U, Maeda Y, et al. 2002. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc Res, 53:993-1001.
83. Shyu KG, Wang MT, Wang BW, et al. 2002. Intramyocardial injection of naked DNA encoding HIF-1 alpha/VP 16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res, 54:576-83.
84. Simons M, Annex BH, Laham RJ, et al. 2002. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation, 105:788-93.
85. Soker S, Takashima S, Miao HQ, et al. 1998. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform- specific receptor for vascular endothelial growth factor. Cell, 92:735-45.
86. Srinath Reddy K, Shah B, Varghese C, et al. 2005. Responding to the threat of chronic diseases in India. Lancet, 366:1744-9.
87. St George JA. 2003. Gene therapy progress and prospects: adenoviral vectors. Gene Ther, 10: 113 5-41.
88. Stewart DJ. 2001 A phase 2, randomized, multicenter, 26-week study to assess the efficacy and safety of BIOBYPASS (AdGVVEGF121) delivered through minimally invasive surgery versus maximum medical treatment in patients with severe angina, advanced coronary artery disease, and no options for revascularizations. Circulation, 106:2986-a (abstract).
89. Su H, Lu R, Kan YW. 2000. Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Natl Acad Sci USA, 97:13801-6.
90. Suri C, Jones PF, Patan S, et al. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 87:1171-80.
91. Symes JF, Losordo DW, Vale PR, et al. 1999. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg, 68:830-6; discussion 836-7.
92. Taniyama Y, Tachibana K, Hiraoka K, et al. 2002. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther, 9:372-80.
93. Thomas CE, Storm TA, Huang Z, et al. 2004. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol, 78:3110-22.
94. Thurston G, Rudge JS, Ioffe E, et al. 2000. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med, 6:460-3.
95. Tomko RP, Xu R, Philipson L. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA, 94:3352-6.
96. Tratschin JD, West MH, Sandbank T, et al. 1984. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyl-transferase. Mol Cell Biol, 4:2072-81.
97. Vale PR, Losordo DW, Milliken CE, et al. 2000. Left ventricular electro-mechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation, 102:965-74.
98. Vincent KA, Shyu KG, Luo Y, et al. 2000. Angiogenesis is induced in a rabbit model of hindlimb ischernia by naked DNA encoding an HIF-1alpha/ VP16 hybrid transcription factor. Circulation, 102:2255-61.
99. Walters RW, Yi SM, Keshavjee S, et al. 2001. Binding of adeno-associated virus type 5 to 2,3 -linked sialic acid is required for gene transfer. J Biol Chem, 276:20610-16.
100. Wang Z, Zhu T, Qiao C, et al. 2005. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol, 23:321-8.
101. Wenger RH, Gassmann M. 1997. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem, 378:609-16.
102. White SJ, Nicklin SA, Buning H, et al. 2004. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation, 109:513-19.
103. Wickham TJ, Mathias P, Cheresh DA, et al. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell, 73:309-19.
104. Xie Q, Bu W, Bhatia S, et al. 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA, 99:10405-10.
105. Yang Y, Haecker SE, Su Q, et al. 1996. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet, 5:1703-12.
106. Yla-Hertmala S, Alitalo K. 2003. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med, 9:694-701.